Oncotarget

Research Papers:

Response to stereotactic ablative radiotherapy in a novel orthotopic model of non-small cell lung cancer

Ayman Oweida, Siham Sabri, Areej Al-Rabea, Mojgan Ebrahimi, Russel Ruo, Richard Fraser, Jan Seuntjens and Bassam Abdulkarim _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:1630-1640. https://doi.org/10.18632/oncotarget.22727

Metrics: PDF 676 views  |   HTML 950 views  |   ?  


Abstract

Ayman Oweida1, Siham Sabri2,3, Areej Al-Rabea2, Mojgan Ebrahimi4, Russel Ruo5, Richard Fraser5, Jan Seuntjens5 and Bassam Abdulkarim2,3

1Department of Radiation Oncology, University of Colorado Denver, Aurora, Colorado 80045, USA

2Division of Radiation Oncology, McGill University Health Center, Montreal, Quebec H4A 3J1, Canada

3Department of Oncology, McGill University Health Center, Montreal, Quebec H4A 3J1, Canada

4Department of Pathology, McGill University Health Center, Montreal, Quebec H4A 3J1, Canada

5Medical Physics Unit, McGill University Health Center, Montreal, Quebec H4A 3J1, Canada

Correspondence to:

Bassam Abdulkarim, email: bassam.abdulkarim@mcgill.ca

Keywords: radiation therapy; lung cancer; radioresistance; metastasis

Received: May 14, 2017     Accepted: October 28, 2017     Published: November 28, 2017

ABSTRACT

Stereotactic ablative radiotherapy (SABR) is the main treatment for inoperable early-stage non-small cell lung cancer (NSCLC). Despite the widespread use of SABR, the biological determinants of response to SABR remain poorly investigated. We developed an orthotopic NSCLC animal model to study the response to clinically-relevant doses of SABR. Image-guided intra-thoracic injection of NSCLC cells was performed in the right lung of nude rats. A highly conformal dose of 34 Gy was delivered in a single fraction using clinical photon energies. Animals were sacrificed 10–60 days post treatment. Lung tumors were assessed for tumor differentiation, proliferation and invasiveness. An analysis of 770 cancer-related genes was performed on tumor-derived cell lines from treated animals at early and late time points after SABR. The majority of animals receiving SABR demonstrated complete response (67%), while 33% demonstrated local failure. 50% of animals with complete response failed distantly. Analysis of cancer-related genes revealed significant differences between tumors treated with SABR and untreated tumors. SABR significantly modulated expression of genes involved in adhesion, migration and angiogenesis. In particular, interleukin-8 (IL8) which plays a critical role in promoting tumor invasion was found to be secreted at high levels after SABR. In vitro invasion assays confirmed SABR-induced invasion and demonstrated induction of IL-8 secretion in multiple NSCLC cell lines. Our findings underscore the importance of developing targeted therapies that can circumvent the pro-invasive effects of SABR in NSCLC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22727